Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Horizon Discovery Ltd.

This article was originally published in Start Up

Executive Summary

Horizon Discovery is creating human isogenic cell lines aimed at making drug discovery faster and more effective, potentially leading to the creation of more targeted or personalized medicines. Their virus-based technique, known as GENESIS, can precisely engineer disease-causing and patient-specific single, double, and triple genetic mutations into normal human cells. GENESIS underpins Horizon's rapidly growing portfolio of X-MAN (Mutant And Normal) cell-line pairs that may help pharmaceutical researchers assess the likely patient response to a potential drug candidate by defining the potential patient responder demographic much earlier in the development time line.

You may also be interested in...



Start-Up Quarterly Statistics, Q4 2009

Highlights from the Q4 2009 review of start-up dealmaking: Fundraising in the biopharma, medical device, and in vitro diagnostics industries totaled $976 million, an 88% increase from the previous quarter, and a 77% jump from Q4 2008's $551 million. Of the total fundraising, 66% or $640 million went to the biopharma industry. Compared with Q3 2009, device fundraising rose by 85% (from $113 million to $209 million) and diagnostics companies raised 72% more (from $74 million to $127 million). The fourth quarter of 2009 saw eight acquisitions, all of them in the biopharma industry. Big Pharmas were busy signing deals with start-ups--Sanofi-Aventis inked three while Roche and Novartis AG each signed two.

Start-Up Quarterly Statistics, Q4 2009

Highlights from the Q4 2009 review of start-up dealmaking: Fundraising in the biopharma, medical device, and in vitro diagnostics industries totaled $976 million, an 88% increase from the previous quarter, and a 77% jump from Q4 2008's $551 million. Of the total fundraising, 66% or $640 million went to the biopharma industry. Compared with Q3 2009, device fundraising rose by 85% (from $113 million to $209 million) and diagnostics companies raised 72% more (from $74 million to $127 million). The fourth quarter of 2009 saw eight acquisitions, all of them in the biopharma industry. Big Pharmas were busy signing deals with start-ups--Sanofi-Aventis inked three while Roche and Novartis AG each signed two.

Start-Up Previews (10/20080

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Making Inroads in Predictive Toxicology," features profiles of Cellumen, GliaGen, Horizon Discovery and SimuGen. Plus these Start-Ups Across Health Care: Acacia Pharma, InspireMD, MicroTransponder and Quotient Diagnostics.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel